KR102783648B1 - (s, e)-4-(디메틸아미노)-n-(3-(4-(2-히드록시-1-페닐에틸아미노)-6-페닐퓨로[2,3-d]피리미딘-5-일)페닐)부트-2-엔아미드 유리 염기의 결정형 - Google Patents
(s, e)-4-(디메틸아미노)-n-(3-(4-(2-히드록시-1-페닐에틸아미노)-6-페닐퓨로[2,3-d]피리미딘-5-일)페닐)부트-2-엔아미드 유리 염기의 결정형 Download PDFInfo
- Publication number
- KR102783648B1 KR102783648B1 KR1020237023847A KR20237023847A KR102783648B1 KR 102783648 B1 KR102783648 B1 KR 102783648B1 KR 1020237023847 A KR1020237023847 A KR 1020237023847A KR 20237023847 A KR20237023847 A KR 20237023847A KR 102783648 B1 KR102783648 B1 KR 102783648B1
- Authority
- KR
- South Korea
- Prior art keywords
- crystalline form
- abt
- free base
- cancer
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163218504P | 2021-07-06 | 2021-07-06 | |
| US63/218,504 | 2021-07-06 | ||
| PCT/US2022/036260 WO2023283269A1 (en) | 2021-07-06 | 2022-07-06 | Crystalline forms of (s, e)-4-(dimethylamino)-n-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)but-2-enamide free base |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20230118963A KR20230118963A (ko) | 2023-08-14 |
| KR102783648B1 true KR102783648B1 (ko) | 2025-03-18 |
Family
ID=84802010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237023847A Active KR102783648B1 (ko) | 2021-07-06 | 2022-07-06 | (s, e)-4-(디메틸아미노)-n-(3-(4-(2-히드록시-1-페닐에틸아미노)-6-페닐퓨로[2,3-d]피리미딘-5-일)페닐)부트-2-엔아미드 유리 염기의 결정형 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12240858B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4330259A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7565118B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102783648B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN116916922B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022307875B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023024853A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3217088A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL308946B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023013093A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI809967B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023283269A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI906763B (zh) * | 2024-02-05 | 2025-12-01 | 財團法人國家衛生研究院 | 表皮生長因子受體抑制劑 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010054285A2 (en) * | 2008-11-10 | 2010-05-14 | National Health Research Institutes | Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors |
| KR101301533B1 (ko) * | 2010-02-09 | 2013-09-04 | 한미사이언스 주식회사 | 암세포 성장 억제 효과를 갖는 신규 피리미딘 유도체 |
-
2022
- 2022-07-05 TW TW111125153A patent/TWI809967B/zh active
- 2022-07-06 IL IL308946A patent/IL308946B2/en unknown
- 2022-07-06 WO PCT/US2022/036260 patent/WO2023283269A1/en not_active Ceased
- 2022-07-06 CN CN202280009812.5A patent/CN116916922B/zh active Active
- 2022-07-06 US US17/858,321 patent/US12240858B2/en active Active
- 2022-07-06 CA CA3217088A patent/CA3217088A1/en active Pending
- 2022-07-06 JP JP2023544357A patent/JP7565118B2/ja active Active
- 2022-07-06 AU AU2022307875A patent/AU2022307875B2/en active Active
- 2022-07-06 BR BR112023024853A patent/BR112023024853A2/pt unknown
- 2022-07-06 KR KR1020237023847A patent/KR102783648B1/ko active Active
- 2022-07-06 MX MX2023013093A patent/MX2023013093A/es unknown
- 2022-07-06 EP EP22838355.0A patent/EP4330259A4/en active Pending
-
2024
- 2024-07-17 US US18/775,916 patent/US20240368175A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023013093A (es) | 2024-04-09 |
| TW202309041A (zh) | 2023-03-01 |
| IL308946A (en) | 2024-01-01 |
| AU2022307875A1 (en) | 2023-11-02 |
| CN116916922A (zh) | 2023-10-20 |
| IL308946B2 (en) | 2026-01-01 |
| JP2024514995A (ja) | 2024-04-04 |
| IL308946B1 (en) | 2025-09-01 |
| CA3217088A1 (en) | 2023-01-12 |
| US20230021909A1 (en) | 2023-01-26 |
| US20240368175A1 (en) | 2024-11-07 |
| WO2023283269A1 (en) | 2023-01-12 |
| CN116916922B (zh) | 2026-01-02 |
| JP7565118B2 (ja) | 2024-10-10 |
| US12240858B2 (en) | 2025-03-04 |
| BR112023024853A2 (pt) | 2024-02-15 |
| AU2022307875B2 (en) | 2024-08-01 |
| KR20230118963A (ko) | 2023-08-14 |
| TWI809967B (zh) | 2023-07-21 |
| EP4330259A4 (en) | 2024-10-09 |
| EP4330259A1 (en) | 2024-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7383652B2 (ja) | B-rafキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 | |
| JP4456079B2 (ja) | {6,7−ビス(2−メトキシ−エトキシ)−キナゾリン−4−イル}−(3e)の多形体 | |
| TW202311259A (zh) | 化合物i的新形式及其應用 | |
| US20230167128A1 (en) | Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production | |
| EP3927696B1 (en) | Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate | |
| ES2650797T3 (es) | Formas cristalinas de (S)-4-amino-N- (1-(4-clorofenil)-3-hidroxipropil)-1-(7H-pirrolo [2,3-d] pirimidin-4-il) piperidina-4-carboxamida | |
| EP3612527B1 (en) | Heterocyclic compounds useful as modulators of acetylcholine receptors | |
| US20240368175A1 (en) | Crystalline forms of (s, e)-4-(dimethylamino)-n-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)but-2-enamide free base | |
| CN114630819A (zh) | 用于预防或治疗癌症的苯甲酰胺衍生物、其制备方法以及包含其作为活性成分的药物组合物 | |
| US9120815B2 (en) | Solid state forms of macrocyclic kinase inhibitors | |
| RU2851691C2 (ru) | Кристаллические формы свободного основания (S,E)-4-(диметиламино)-N-(3-(4-(2-гидрокси-1-фенилэтиламино)-6-фенилфуро[2,3-d]пиримидин-5-ил)фенил)бут-2-енамида | |
| KR20160075824A (ko) | 2-(4-(2-(1-이소프로필-3-메틸-1H-1,2,4-트라이아졸-5-일)-5,6-다이하이드로벤조[f]이미다조[1,2-d][1,4]옥사제핀-9-일)-1H-피라졸-1-일)-2-메틸프로판아미드의 다형체, 이의 제조 방법 및 이의 약학적 용도 | |
| HK40094095A (en) | Crystalline forms of (s, e)-4-(dimethylamino)-n-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)but-2-enamide free base | |
| EP3750894B1 (en) | Urea-substituted aromatic ring-linked dioxazoline compound, preparation method therefor, and uses thereof | |
| TW202517624A (zh) | Mek免疫腫瘤抑制劑醫藥組合物 | |
| KR20250098089A (ko) | 퀴나졸린 유도체 화합물의 신규한 염 및 이의 제조방법 | |
| US20210340142A1 (en) | Salt form and crystal form of novel azatricyclic compound and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A302 | Request for accelerated examination | ||
| PA0302 | Request for accelerated examination |
St.27 status event code: A-1-2-D10-D17-exm-PA0302 St.27 status event code: A-1-2-D10-D16-exm-PA0302 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PX0901 | Re-examination |
St.27 status event code: A-2-3-E10-E12-rex-PX0901 |
|
| PX0701 | Decision of registration after re-examination |
St.27 status event code: A-3-4-F10-F13-rex-PX0701 |
|
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R11-asn-PN2301 |